Navigation Links
Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
Date:2/21/2008

SOMERSET, N.J., Feb. 21 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that in vitro and in vivo data presented at the 5th Cancer Drug Research & Development conference show the genes affected and biological pathways impacted by ONCONASE stimulated intracellular events as revealed by expression profiling of human malignant mesothelioma cell lines. Data presented also show that ONCONASE conjugates effectively kill human cancer cells in cell culture and murine models of cancer.

Susanna Rybak, Ph.D., a member of Alfacell's scientific advisory board, presented a poster entitled "ONCONASE (ranpirnase): Intracellular Activity and Extracellular Selectivity." The data demonstrated that 181 genes were consistently up- and down-regulated by ONCONASE and that the genes involved in triggering apoptosis (programmed cell death) and the intracellular MAPK signaling pathway were impacted by ONCONASE in vitro. Additionally, pre-clinical data in mice demonstrated the relative potency of chemical conjugates of ONCONASE. These findings further support the research of next generation targeted ONCONASE fusion proteins in an effort to develop compounds with improved tumor penetrating abilities. The research was conducted in collaboration with Alfacell at Fox Chase Cancer Center and the University of Duisburg-Essen.

"This work may explain the intrinsic anti-tumor activity seen after ONCONASE treatment through the identification of the specific genes affected and the biological pathways impacted," said Dr. Rybak. "Additionally, this data is helping us to better understand the optimal intracellular pathways for developing antibody targeted ONCONASE compounds."

"The data presented further illuminates the potential for ONCONASE to simultaneously switch on and off numerous genes controlling major regulatory processes in the cell life cycle, and underscores that ONCONASE works selectively and does not appear to kill cells indiscriminately," added Kuslima Shogen, Alfacell's chief executive officer. "This research represents an important step forward in our continuing efforts to create targeted ONCONASE fusion proteins and to bring them forward into the clinic."

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of

ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media and Investor Contact:

David Schull or Wendy Lau

Russo Partners

212-845-4271

david.schull@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
4. Clinical Trial Participation Unaffected by Disclosure of Investigators Financial Stake, Food and Drug Law Journal Article Finds
5. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
6. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... -- ivWatch LLC, a medical device company focused on improving ... pleased to announce it was the Bronze Winner last ... Equipment at the 2017 Medical Design Excellence Awards (MDEAs), ... award was presented by Medical Device and Diagnostics Industry ... New York during MD&M East, the ...
(Date:6/13/2017)... 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that the U.S. Food and Drug Administration (FDA) has notified ... relating to its Zhejiang, China manufacturing ... "The successful clearance of the Warning Letter related to ... is a measure of the progress we have made in ...
(Date:6/10/2017)... , June 9, 2017  Shane K. Burchfield, DPM, is recognized ... excellence as a Podiatrist in Alabama . ... Family First Foot Care. He brings over 20 years of experience, ... management and healthcare, to his role. ... Care, PC is pleased to welcome you to his ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... ... June is Men’s Health Month and the focus is on prostate cancer. Second ... U.S. and the third most common cause of cancer related death today; lung cancer remains ... be diagnosed with prostate cancer during his lifetime. Those at highest risk are ...
(Date:6/24/2017)... ... 2017 , ... The weather is heating up and the days are getting ... be aware that the summer months provide more than warmer temperatures that are perfect ... be negatively affected from direct exposure to the sun. When it comes to the ...
(Date:6/23/2017)... ... ... By scoring 100% for fiscal management and accountability, the Arthritis National Research ... Charity Navigator, validating ANRF's work as a top charity in America. , This achievement ... earns ANRF a spot on their “ 10 Charities Worth Watching ” list as ...
(Date:6/23/2017)... ... 2017 , ... Dr. Ran Y. Rubinstein , a ... offering three new minimally invasive procedures to patients who want a younger and ... Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich plasma (PRP) ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted Dr. ... come up with a proprietary technique that he calls the AuraLyft Facelift. ... For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. , ...
Breaking Medicine News(10 mins):